CTEVClaritev Corporation
Claritev Corporation (CTEV) sells professional services in the healthcare and digital health sectors, leveraging its platform to deliver solutions for mental health benefits navigation and digital health innovation. The next catalyst is Oct 15, 2026 — Activist Intervention / Takeover Speculation Peaks, which will test whether the company can attract strategic bidders or fend off activist pressure amid its debt load and legal exposure.
- Revenue hit $989.68M in 2026, but net income remains -$265.18M, with free cash flow in negative territory.
- The company has a negative shareholders’ equity of -$173.90M and a debt-to-equity ratio of -26.61x, suggesting a leveraged capital structure.
- Net margin (TTM) is -26.8%, and revenue growth YoY is 3.7%, indicating persistent pressure on profitability.
The Read
Claritev's stock surged about 30% despite rising interest rate concerns due to strong institutional buying and no refinancing issues, but later plunged over 40% following Q1 losses and a securities fraud investigation that severely damaged investor confidence.
The schedule
- Thu15Oct
The speculation tests whether activist pressure can unlock value through restructuring or M&A, unlike the last speculative peak that failed to materialize.
- Thu5Nov
The earnings release tests whether the company can reset guidance and stabilize cash flow, unlike the last print which missed expectations on liquidity.
- Fri15Jan
The verdict tests whether restructuring or M&A can stabilize the balance sheet, unlike the last restructuring which failed to resolve liquidity concerns.
- Thu4Feb
The outlook tests whether the company can stabilize its solvency and reset guidance, unlike the last print which failed to address liquidity concerns.
- Thu6May
The earnings release tests whether the company can reset guidance and stabilize cash flow, unlike the last print which missed expectations on liquidity.
- Thu5Aug
Past
- Thu6Aug
Actual outcome: Bull · $34.12 at outcome
CTEV reported EPS of -4.41, matching estimates, but the strategic asset sale update and positive forward guidance signaled a path to recovery. The stock rallied 27.8% as investors focused on the potential $26.00 bull target and the company's plan to reduce debt, moving past the initial bearish concerns.
Q2 2026 earnings on 2026-08-06 will spotlight CTEV's massive debt load. A strategic asset sale could secure a $26.00 recovery, but ongoing burn sets an adverse $12.50 fallback.
- Wed15Jul
Actual outcome: Bear · $23.80 at outcome
The stock fell 20.1% following the SEC filing update, indicating investor concern over the legal investigation. The outcome suggests that the market reacted negatively to the potential implications of the inquiry, which likely raised doubts about the company's compliance and future prospects. The price movement aligns with the bear floor, reflecting heightened risk aversion and uncertainty around the company's regulatory exposure.
The market awaits a crucial update regarding the SEC inquiry on 2026-07-15. Clearance could drive CTEV back to $35.00, while further findings risk an $18.00 floor.
- Thu7May
Actual outcome: Bear · $23.47 at outcome
Claritev reported Q1 results with an EPS loss of $4.41 that matched estimates and revenue that topped expectations, driven by strong sales momentum. Despite the positive top-line performance and management's reaffirmed full-year outlook, the stock's reaction was muted and slightly negative, ultimately pressured by the announcement of a securities fraud investigation on the outcome date.
With a massive $4.63B debt load against a small equity base, Claritev's May 5 print will be heavily scrutinized for cash flow sustainability.
- Wed18Mar
Actual outcome: Bull · $20.59 at outcome
Despite initial concerns regarding rising interest rates and the company's $4.6 billion debt load, Claritev's stock rallied significantly, easily surpassing the $18.50 bull target. The absence of negative refinancing developments, coupled with institutional accumulation from firms like Citigroup, indicated that the market largely shrugged off the macro headwinds and remained confident in the company's underlying fundamentals.
Market reaction to the Trump administration's fiscal policy outlook and its impact on highly levered companies like Claritev ($4.6B debt).
